ClinicalTrials.gg
CompletedNCT00526760Updated Jun 30, 2015

Long-term Clinical Study Evaluating the Safety and Efficacy of Dexmedetomidine in ICU Subjects

A Phase 3 interventional study of Dexmedetomidine in Sedation, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 10 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-06-30.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Evaluate efficacy and safety of dexmedetomidine long term administration in ICU patients who require more than 24 hours sedation.

Read the detailed description

According to the current dexmedetomidine indication, the duration of dexmedetomidine administration is limited within 24 hours. However, there is a strong demand from the medical specialists for continued administration of dexmedetomidine in excess of 24 hours in the medical practice because a large number of patients require sedation for more than 24 hours in ICU. To meet such clinical demand, it was planned to conduct a phase III long-term administration study of dexmedetomidine to obtain the approval on the infusion of dexmedetomidine for more than 24 hours.

02

Conditions studied

  • Sedation

Keywords

  • Dexmedetomidine, Sedation, Long-term, Phase 3
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient or legally acceptable representative (if acceptable by Institutional Review Board/Ethics Committee) has signed and dated the after the study had been fully explained.
  2. Patient is male or female, at least 20 years of age.
  3. In case of surgical ICU patient, who is in condition of (ASA) I to III Class preoperatively.
  4. Patient is on mechanical ventilation and anticipated to require sedation more than 24 hours following a surgery.
  5. If patient is female with child bearing potential, she is to be non-pregnant, and not lactating.

Exclusion criteria

Exclusion Criteria:

  1. Patient has serious central nervous system (CNS) trauma.
  2. Patient requires the use of neuromuscular blocking agents after admission to ICU, except for the insertion of the endotracheal tube.
  3. Patient is hospitalized for drug overdose within the last 30 days.
  4. Patient in whom alpha-2 antagonists or alpha-2 agonists are .
  5. Patient is currently being treated or has been treated within the last 30 days with alpha-2 agonist or antagonist.
  6. Patient has participated in a trial with any experimental drug within 30 days prior to admission to the ICU.
  7. Terminally ill patient, whose life duration expectancy is no more or around 30 days.
  8. Patient is considered unable to undergo any procedure required by the protocol.
  9. Patient with excessive bleeding which will likely require surgery.
  10. In the Investigator's opinion, patient has any symptom or factor, which might increase risk to the patient or preclude obtaining satisfactory study data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Drug: Dexmedetomidine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence rate of adverse drug reactions of hypotension, hypertension and bradycardia which correspond to the protocol definitions

    Definition: * Hypotension: dosing start or dose increase of vasopressor drug or use of fluid bolus ≥500 mL within 1 hour resulting from SBP\<60mmHg, DBP\<40mmHg or ≥50% lower than baseline. * Hypertension: dosing start or dose increase of intravenous anti-hypertensive medication resulting from SBP\>160, DBP\>100 or. ≥50% higher than baseline. * Bradycardia: dosing start or dose increase of positive chronotropic medication or use of pacemaker resulting from heart rate \<40bpm or ≥50% lower than baseline.

    Time frame: Prior to study drug infusion, during the study drug infusion and 24 hours after study drug infusion end; maximum ≤28 days.

Secondary outcomes

  1. Percentage of with a Richmond Agitation-Sedation Sedation Score ≤0 during the study drug infusion

    Time frame: Prior to study drug infusion, during the study drug infusion and 24 hours after study drug infusion end; maximum ≤28 days.

  2. Percentage of time with a Richmond Agitation-Sedation Sedation Score =0, -1,-2 during the study drug infusion

    Time frame: Prior to study drug infusion, during the study drug infusion and 24 hours after study drug infusion end; maximum ≤28 days.

  3. Administration frequency and dosage of additional sedatives

    Time frame: Prior to study drug infusion, during the study drug infusion and 24 hours after study drug infusion end; maximum ≤28 days.

  4. Administration frequency and dosage of additional analgesics

    Time frame: Prior to study drug infusion, during the study drug infusion and 24 hours after study drug infusion end; maximum ≤28 days.

07

Study locations

10 sites
  • Hyogo Medical University Hospital
    Nishinomiya-City, Hyogo 663-8501, Japan
  • Kagoshima University Hospital
    Kagoshima-City, Kagoshima 890-8520, Japan
  • Kinki University Hospital
    Osakasayama-City, Osaka 589-8511, Japan
  • Osaka University Hospital
    Suita-City, Osaka 565-0871, Japan
  • Hamamatsu Medical University Hospital
    Hamamatsu-City, Shizuoka 431-3192, Japan
  • Nippon Medical School Hospital
    Bunkyo-ku, Tokyo 113-8603, Japan
  • Jikei University Hospital
    Minato-ku, Tokyo 105-8741, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Keio University Hospital
    Sinjuku-ku, Tokyo 160-8582, Japan
  • Yamanashi University Hospital
    Chuo-city, Yamanashi 409-3898, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2007
First posted
Sep 10, 2007
Start
Oct 2007
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Last update
Jun 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00526760
Collaborators
Maruishi Pharmaceutical
Responsible party
Sponsor
First posted
Sep 10, 2007
Start date
Oct 2007
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Jun 30, 2015

Study contacts

Misa Kawai
study director · Hospira, now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion